Luteinized unruptured follicle syndrome increased by inactive disease and selective cyclooxygenase 2 inhibitors in women with inflammatory arthropathies

Mihaela C Micu, Mihaela Micu, Romeo Micu, Monika Ostensen, Monika Østensen
Arthritis care & research · 2011 · vol. 63(9) , pp. 1334–1338 · doi:10.1002/acr.20510 · PMID:21618455 · W2009559697
Observational OA: closed CC0 ⤵ 8 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

Nonsteroidal anti-inflammatory drugs, especially the COX-2 inhibitor etoricoxib, increased luteinized unruptured follicle syndrome in women with inflammatory arthropathies, particularly those with inactive disease.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: Administration of nonsteroidal antiinflammatory drugs (NSAIDs) may impair fertility. The occurrence of the luteinized unruptured follicle (LUF) syndrome was assessed in women with inflammatory arthropathies exposed to NSAIDs and compared to that in nonexposed women. METHODS: Fourteen patients with inflammatory rheumatic disease, 29 women with noninflammatory musculoskeletal conditions, and 449 women not exposed to NSAIDs were studied by intravaginal ultrasound monitoring for follicular development and ovulation in 1 or more menstrual cycles. Disease activity was assessed in inflammatory rheumatic disease. RESULTS: In 59 monitored cycles of patients with continuous NSAID exposure, 35.6% of LUF syndromes occurred compared to 3.4% of LUF syndromes in untreated women (P < 0.001). Etoricoxib was responsible for 75% of LUF syndromes in patients exposed continuously, whereas diclofenac generated 15% of LUF syndromes. An ibuprofen dosage of 1,600 mg/day did not induce LUF syndrome either at continuous periovulatory or discontinuous exposure. Interestingly, the frequency of LUF syndrome was 46.2% in patients with inactive inflammatory disease compared to 15% in patients with active disease (P = 0.023). Etoricoxib generated LUF syndrome in 94.2% of the cases with inactive disease versus 28.6% in patients with active disease (P = 0.003). CONCLUSION: NSAIDs increased the risk of the LUF syndrome, particularly in patients with inactive disease. The selective cyclooxygenase 2 (COX-2) inhibitor etoricoxib was a more potent inductor of LUF syndrome than nonselective COX inhibitors. Continuous periovulatory exposure to NSAIDs should be avoided when planning a pregnancy in patients with rheumatic diseases.

My notes (saved in your browser only)

MeSH descriptors

Anti-Inflammatory Agents, Non-Steroidal Cyclooxygenase 2 Inhibitors Fertility Infertility, Female Inflammation Ovarian Follicle Ovulation Rheumatic Diseases Adult Anti-Inflammatory Agents, Non-Steroidal Case-Control Studies Chi-Square Distribution Cyclooxygenase 2 Inhibitors Diclofenac Diclofenac Etoricoxib Female Fertility Humans Ibuprofen

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (19)

Cited by (7)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:09:02.791371+00:00
License: CC0 · commercial use OK